Free tool
FAERS Monitor: Sogroya
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming BLA 761156 or its brand name (Sogroya, Somapacitan-Beco). Reports on generic versions are filed under their own applications.
Reports
181
Serious
115
64% of reports
Hospitalization
51
Death reported
10
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- headache15
- pyrexia8
- arthralgia7
- fatigue7
- vomiting7
- hospitalisation6
- pain in extremity6
- rash6
- abdominal pain5
- asthenia5
- condition aggravated5
- decreased appetite5
- dehydration5
- hypoglycaemia5
- seizure5
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2022 | 2 |
| 2023 | 8 |
| 2024 | 58 |
| 2025 | 53 |
| 2026 | 60 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,053,978 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| hypoglycaemiaSignal | 5 | 12.0 | 5.0 | 40 |
| seizureSignal | 5 | 5.0 | 2.1 | 12 |
| hospitalisationSignal | 6 | 4.5 | 2.1 | 13 |
| dehydrationSignal | 5 | 4.4 | 1.8 | 10 |
| headacheSignal | 15 | 2.8 | 1.7 | 16 |
| pyrexiaSignal | 8 | 2.7 | 1.4 | 7 |
| decreased appetite | 5 | 2.5 | 1.1 | 3 |
| abdominal pain | 5 | 2.5 | 1.1 | 3 |
| pain in extremity | 6 | 2.4 | 1.1 | 4 |
| arthralgia | 7 | 2.0 | 0.9 | 2 |
| condition aggravated | 5 | 1.9 | 0.8 | 1 |
| vomiting | 7 | 1.7 | 0.8 | 2 |
| rash | 6 | 1.6 | 0.7 | 1 |
| asthenia | 5 | 1.5 | 0.7 | 1 |
| fatigue | 7 | 1.0 | 0.5 | 0 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.